BioMarin Pharmaceutical Inc. (BMRN) – What Are Brokerages Saying About This Stock?

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-five analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $88.38.

Several equities analysts have weighed in on BMRN shares. Canaccord Genuity Group raised their target price on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Oppenheimer boosted their target price on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an “outperform” rating in a research note on Friday, August 7th. Barclays increased their price target on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. JPMorgan Chase & Co. lifted their price objective on BioMarin Pharmaceutical from $86.00 to $87.00 and gave the stock an “overweight” rating in a report on Tuesday, October 20th. Finally, Weiss Ratings lowered BioMarin Pharmaceutical from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 18th.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ:BMRN opened at $58.51 on Monday. The company’s 50-day moving average is $60.62 and its 200 day moving average is $58.44. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The company has a market capitalization of $11.33 billion, a P/E ratio of 158.14, a price-to-earnings-growth ratio of 0.64 and a beta of 0.21. BioMarin Pharmaceutical has a fifty-two week low of $49.26 and a fifty-two week high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.25. The company had revenue of $989.71 million during the quarter, compared to analyst estimates of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The firm’s revenue for the quarter was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, equities research analysts forecast that BioMarin Pharmaceutical will post 2.59 earnings per share for the current year.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BMRN. Bfsg LLC bought a new position in BioMarin Pharmaceutical in the 3rd quarter worth approximately $1,052,000. Oregon Public Employees Retirement Fund grew its stake in BioMarin Pharmaceutical by 0.5% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 40,117 shares of the biotechnology company’s stock valued at $2,407,000 after buying an additional 200 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in BioMarin Pharmaceutical during the 3rd quarter valued at $186,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in BioMarin Pharmaceutical during the 3rd quarter valued at $705,000. Finally, Profund Advisors LLC raised its holdings in BioMarin Pharmaceutical by 34.3% during the 3rd quarter. Profund Advisors LLC now owns 37,548 shares of the biotechnology company’s stock valued at $2,253,000 after acquiring an additional 9,582 shares during the period. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.